Table 1 Demographics of patients.
Clinical characteristics | Nab-PC (N = 55) | Decetaxel(N = 216) | All (N = 271) |
|---|---|---|---|
No.(%) | No.(%) | No.(%) | |
Age(years) | |||
Median | 59 | 57 | 58 |
IQR | 52–66 | 50–65 | 51–65 |
<70 | 50(90%) | 197(91.2%) | 247(91.1%) |
≥70 | 5(10.0%) | 19(8.8%) | 24(8.9%) |
Sex | |||
Male | 45(81.8%) | 180(83.3%) | 225(83.0%) |
Female | 10(18.2%) | 36(16.7%) | 46(17.0%) |
Smoking | |||
Yes | 44(80%) | 151(69.9%) | 195(72.0%) |
No | 11(20%) | 65(30.1%) | 76(28.0%) |
ECOG PS | |||
0 | 18(32.7%) | 65(30.1%) | 83(30.6%) |
1 | 37(67.3%) | 151(69.9%) | 188(69.4%) |
Histology | |||
Squamous cell carcinoma | 24(43.6%) | 93(43.1%) | 117(43.2%) |
Adenocarcinoma | 28(50.9%) | 112(51.9%) | 140(51.7%) |
Large-cell carcinoma | 2(3.6%) | 4(1.9%) | 6(2.2%) |
Other | 1(1.8%) | 7(3.2%) | 8(3.0%) |
Clinical Stage | |||
IIIB | 20(36.4%) | 73(33.8%) | 93(34.3%) |
IV | 35(63.6%) | 143(66.2%) | 178(65.7%) |
Prior Therapy | |||
Surgery | 9(16.4%) | 26(12.0%) | 35(12.9%) |
Radiation therapy | 1(1.8%) | 3(1.4%) | 4(1.5%) |
Ajuvant Chemotherapy | 4(7.3%) | 10(4.6%) | 14(5.2%) |
